The MIND Institute for Neurological Development is pleased to introduce Neurofeedback and Interactive Metronome training to Southeast Ohio. These therapies incorporate hi-tech state of the art equipment with the expertise of our Directors and staff. This is a uniquely doctor directed program used to help children (and adults!) with Attention Deficit Disorder and Hyperactivity: ADD/ADHD! On this site you will find information that has helped countless others. Please look it over and then ask yourself; Are you tired of running from doctor to doctor only to play “Russian Roulette” with different medications for your child? “Here try this drug, that didn’t work? Try this one!” Are you tired of giving your child drugs that don’t fix the problem? Are you worried about who your child will become if something positive isn’t done? Does your child continue to struggle in school or struggle with family and peer relationships? Does your child seem “out of it” on the medications- or WORSE, needs other medications to counteract the side-effects? We are here to tell you that there is NEW HOPE!
Frequently Asked Questions
Is my child a candidate for a Neuro Care program?
Not all children will be accepted for training. Neuro Care’s Directors will make a determination of acceptance into the program after an initial parent interview, Quantitative EEG (“Brain-Map”), exam and child evaluation.
Is the Brain-training in the program safe?
Yes, of course- extremely safe and painless. To the average person Neurofeedback looks like they are watching a movie that stops when they fidget. The other therapies look like they are tapping stomping or clapping to a beat, like play or dance with lights and sound typically thrown in.
Does my child need to stop taking my medications?
Please be advised that Neuro Care staff will never tell you to stop giving your child medications. That’s called practicing medicine without a license. As your child’s symptoms improve during the course of care, Dr. Russ and Dr. Heather will recommend that you return to your physician with your child to adjust medication levels.
Will my insurance cover a program?
Few insurances cover the program. We’ve made it cost-effective for parents by offering package discounts. Others will find that financing is the easiest option.
How much is an ADHD training program?
It varies due to individual exam findings. After the initial parent interview, qEEG/Brain-Map, exam, and thorough review of your case, Dr. Russ and Dr. Heather will determine the course of care for your child’s specific case.
How long is a program?
Most children are seen 1 to 3 times per week for 2-6 months.
About Dr. Russ
Dr. Russel Schroder DC, DACNB, FACFN is a Board Certified Chiropractic Neurologist and Fellow in the American College of Neurology. Dr. Schroder is the only Board Certified Chiropractic Neurologist and Functional Neurologist in the region. Since developing the CTX Method Functional Neurology Program Dr. Schroder has helped thousands of patients find lasting pain relief and healing through his advanced non-surgical and drug-free treatments and therapy programs.
Dr. Russ has advanced post-doctoral training in Spinal Rehabilitation, Sports Injury Management, Fibromyalgia Care, Nutritional Neurology, Non-Surgical Decompression, Functional Blood Analysis, Thyroid Management, Functional Endocrinology, Motor Vehicle Injuries, Herniated, Degenerated and Bulged Disc Treatment and more.
Biol Psychol. 2013 Sep;94(1):12-21. doi: 10.1016/j.biopsycho.2013.04.015. Epub 2013 May 9.
Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up. Meisel V, Servera M, Garcia-Banda G, Cardo E, Moreno I.
Research Institute on Health Sciences (IUNICS), University of Balearic Islands (UIB), Ctra. de Valldemossa, km 7.5, 07122 Palma de Majorca, Spain. email@example.com
The present study is a randomized controlled trial that aims to evaluate the efficacy of Neurofeedback compared to standard pharmacological intervention in the treatment of attention deficit/hyperactivity disorder (ADHD). The final sample consisted of 23 children with ADHD (11 boys and 12 girls, 7-14 years old). Participants carried out 40 theta/beta training sessions or received methylphenidate. Behavioral rating scales were completed by fathers, mothers, and teachers at pre-, post-treatment, two-, and six-month naturalistic follow-up. In both groups, similar significant reductions were reported in ADHD functional impairment by parents; and in primary ADHD symptoms by parents and teachers. However, significant academic performance improvements were only detected in the Neurofeedback group. Our findings provide new evidence for the efficacy of Neurofeedback, and contribute to enlarge the range of non-pharmacological ADHD intervention choices. To our knowledge, this is the first randomized controlled trial with a six-month follow-up that compares Neurofeedback and stimulant medication in ADHD.
Biofeedback Self Regul. 1995 Mar;20(1):83-99.
Evaluation of the effectiveness of EEG neurofeedback training for ADHD in a clinical setting as measured by changes in T.O.V.A. scores, behavioral ratings, and WISC-R performance. Lubar JF, Swartwood MO, Swartwood JN, O’Donnell PH.
University of Tennessee, Knoxville 37996-0900, USA.
A study with three component parts was performed to assess the effectiveness of neurofeedback treatment for Attention Deficit/Hyperactivity Disorder (ADHD). The subject pool consisted of 23 children and adolescents ranging in age from 8 to 19 years with a mean of 11.4 years who participated in a 2- to 3-month summer program of intensive neurofeedback training. Feedback was contingent on the production of 16-20 hertz (beta) activity in the absence of 4-8 hertz (theta) activity. Posttraining changes in EEG activity, T.O.V.A. performance, (ADDES) behavior ratings, and WISC-R performance were assessed. Part I indicated that subjects who successfully decreased theta activity showed significant improvement in T.O.V.A. performance; Part II revealed significant improvement in parent ratings following neurofeedback training; and Part III indicated significant increases in WISC-R scores following neurofeedback training. This study is significant in that it examines the effects of neurofeedback training on both objective and subjective measures under relatively controlled conditions. Our findings corroborate and extend previous research, indicating that neurofeedback training can be an appropriate and efficacious treatment for children with ADHD.
Appl Psychophysiol Biofeedback. 2005 Dec;30(4):365-73.
Neurofeedback: an alternative and efficacious treatment for Attention Deficit Hyperactivity Disorder. Fox DJ, Tharp DF, Fox LC.
Advanced Neurotherapy Solutions, College Station, Texas 77840, USA. firstname.lastname@example.org
Current research has shown that neurofeedback, or EEG biofeedback as it is sometimes called, is a viable alternative treatment for Attention Deficit Hyperactivity Disorder (ADHD). The aim of this article is to illustrate current treatment modalities(s), compare them to neurofeedback, and present the benefits of utilizing this method of treatment to control and potentially alleviate the symptoms of ADHD. In addition, this article examines the prevalence rates and possible etiology of ADHD, the factors associated with ADHD and brain dysfunction, the current pharmacological treatments of ADHD, Ritalin, and the potential risks and side effects. Behavior modification and cognitive behavioral treatment for ADHD is discussed as well. Lastly, a brief history of the study of neurofeedback, treatment successes and clinical benefits, comparisons to medication, and limitations are presented.
Appl Psychophysiol Biofeedback. 2004 Dec;29(4):233-43.
The effectiveness of neurofeedback and stimulant drugs in treating AD/HD: part II. Replication. Rossiter T.
This study replicated T. R. Rossiter and T. J. La Vaque (1995) with a larger sample, expanded age range, and improved statistical analysis. Thirty-one ADIHD patients who chose stimulant drug (MED) treatment were matched with 31 patients who chose a neurofeedback (EEG) treatment program. EEG patients received either office (n = 14) or home (n = 17) neurofeedback. Stimulants for MED patients were titrated using the Test of Variables of Attention (TOVA). EEG (effect size [ES] = 1.01-1.71) and MED (ES = 0.80-1.80) groups showed statistically and clinically significant improvement on TOVA measures of attention, impulse control, processing speed, and variability in attention. The EEG biofeedback group demonstrated statistically and clinically significant improvement on behavioral measures (Behavior Assessment System for Children, ES = 1.16-1.78, and Brown Attention Deficit Disorder Scales, ES = 1.59). TOVA gain scores for the EEG and MED groups were not significantly different. More importantly, confidence interval and nonequivalence null hypothesis testing confirmed that the neurofeedback program produced patient outcomes equivalent to those obtained with stimulant drugs. An effectiveness research design places some limitations on the conclusions that can be drawn.
J Clin Psychol. 2005 May;61(5):621-5.
Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder. Butnik SM.
ADDVANTAGE, PLLC, Richmond, VA 23226, USA.
Neurofeedback is being utilized more commonly today in treating individuals who have attention deficit hyperactivity disorder (ADHD). Neurofeedback, which is based on theories that recognize the organic basis of ADHD, utilizes biofeedback to guide individuals to regulate their brain activity. Neurofeedback relies on research that has demonstrated that most individuals who have ADHD, as compared to matched peers, have excess slow wave activity and reduced fast wave activity. It provides immediate feedback to the individual about his or her brain wave activity in the form of a video game, whose action is influenced by the individual’s meeting predetermined thresholds of brain activity. Over several sessions of using the video and auditory feedback, individuals reduce their slow wave activity and/or increase their fast wave activity. Individuals who complete a course of training sessions often show reduced primary ADHD symptoms. Research has shown that neurofeedback outcomes compare favorably to those of stimulant medication.
Journal of Clinical EEG & Neuroscience, July, 2009
Efficacy of Neurofeedback Treatment in ADHD: The Effects on Inattention, Impulsivity and Hyperactivity: a Meta-Analysis. by Arns M, de Ridder S, Strehl U, Breteler M and Coenen A
Arns M, de Ridder S, Strehl U, Breteler M and Coenen A
Since the first reports of neurofeedback treatment in Attention Deficit Hyperactivity Disorder (ADHD) in 1976, many studies have investigated the effects of neurofeedback on different symptoms of ADHD such as inattention, impulsivity and hyperactivity. This technique is also used by many practitioners, but the question as to the evidence-based level of this treatment is still unclear. In this study selected research on neurofeedback treatment for ADHD was collected and a meta-analysis was performed. Both prospective controlled studies and studies employing a pre- and post-design found large effect sizes (ES) for neurofeedback on impulsivity and inattention and a medium ES for hyperactivity. Randomized studies demonstrated a lower ES for hyperactivity suggesting that hyperactivity is probably most sensitive to nonspecific treatment factors. Due to the inclusion of some very recent and sound methodological studies in this meta-analysis, potential confounding factors such as small studies, lack of randomization in previous studies and a lack of adequate control groups have been addressed, and the clinical effects of neurofeedback in the treatment of ADHD can be regarded as clinically meaningful. Three randomized studies have employed a semi-active control group which can be regarded as a credible sham control providing an equal level of cognitive training and client-therapist interaction. Therefore, in line with the AAPB and ISNR guidelines for rating clinical efficacy, we conclude that neurofeedback treatment for ADHD can be considered “Efficacious and Specific” (Level 5) with a large ES for inattention and impulsivity and a medium ES for hyperactivity.